Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
GlobalData on MSN11d
Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
Novo Nordisk is eyeing up further indications for its blockbuster drug such as a potential treatment for metabolic ...
FiercePharma11d
Novo Nordisk expands Ozempic's turf with new FDA nod to curb kidney disease risks
When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...
EurekAlert!12d
Study shows promise for treating core symptom of frontotemporal dementia
A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...
Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today
Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...
Morningstar4d
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth
Novo Nordisk accounts for 34% of the global diabetes ... fatty liver disease, sleep apnea, and Alzheimer's, and Novo and Lilly are running phase 3 trials of semaglutide and tirzepatide in many ...
The Financial Express11d
USFDA gives nod to Novo Nordisk’s Ozempic to reduce risk of kidney failure
Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...
US FDA approves Novo Nordisk's Ozempic to reduce risk of kidney diseases in diabetic patients
Breakthrough in diabetes treatment! The US FDA approves Ozempic for reducing kidney disease risk in diabetic patients. Learn ...